PT-141 (Bremelanotide): Research, Mechanism, and Clinical Evidence for Sexual Function

What Is PT-141?

PT-141 (bremelanotide, brand name Vyleesi) is an FDA-approved melanocortin receptor agonist peptide that enhances sexual desire through central nervous system pathways, making it mechanistically distinct from drugs that address erectile mechanics.

PT-141 is a peptide that increases sexual desire by acting on receptors in the brain. Unlike Viagra-type drugs that improve blood flow, PT-141 targets the motivation and wanting side of sexual arousal. It’s one of the few peptides with full FDA approval, though only for one specific condition in premenopausal women.

PT-141 is known pharmaceutically as bremelanotide. It was approved by the FDA in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is sold under the brand name Vyleesi. It represents one of the few peptides discussed in research communities that has achieved full FDA regulatory approval.

PT-141’s development history is unusual. It was derived from Melanotan II, a peptide originally developed as a tanning agent. During Melanotan II trials, researchers observed that subjects experienced spontaneous sexual arousal as a side effect. This was a serendipitous finding. It led to the isolation and development of PT-141 as a targeted compound for sexual function.

The critical distinction from phosphodiesterase-5 (PDE5) inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) is the site of action. PT-141 acts in the brain to increase sexual desire. PDE5 inhibitors act on blood vessels to facilitate erection. PT-141 addresses wanting; PDE5 inhibitors address mechanics.

Who this page is for — and who it isn’t for

This page is for researchers, clinicians, and individuals seeking an evidence-based understanding of bremelanotide’s pharmacology and clinical data. It is not a self-treatment guide. Sexual health involves complex physiological and psychological factors that warrant professional evaluation. PT-141 is available by prescription as Vyleesi — this article covers both the approved product and research-context use.

How PT-141 Works

PT-141 activates melanocortin-4 receptors (MC4R) in brain regions governing sexual motivation and reward, producing its effects through central nervous system pathways rather than peripheral vascular mechanisms.

Melanocortin-4 Receptor Activation

PT-141 primarily activates the melanocortin-4 receptor (MC4R), expressed in brain regions involved in sexual behavior, reward, and motivation:

• Hypothalamus. The master regulator of sexual behavior and hormonal signaling.
• Medial preoptic area. Directly involved in sexual motivation.
• Limbic system. Reward and desire pathways.

MC4R activation by PT-141 triggers downstream signaling through oxytocin and dopamine pathways, which are the neurochemical substrates of sexual desire and arousal (Pfaus et al., 2013).

Central vs. Peripheral Mechanism

This distinction is fundamental to understanding PT-141:

• PDE5 inhibitors (sildenafil, tadalafil) act peripherally on blood vessels, producing erection through hemodynamic changes. They have no effect on desire.
• PT-141 acts centrally in the brain, increasing sexual motivation. Arousal follows from enhanced desire rather than from vascular manipulation.

This central mechanism explains why PT-141 is effective in both men and women — the melanocortin system governs sexual desire in both sexes. It also explains its utility in conditions where desire is the primary deficit, which PDE5 inhibitors cannot address.

Additional Melanocortin Effects

PT-141 activates MC3R and MC1R to varying degrees, producing secondary effects:

• MC1R activation. Can cause transient, mild skin darkening (a shared property with Melanotan II, though much less pronounced at standard PT-141 doses).
• MC3R activation. May contribute to appetite modulation.
• MC4R remains the primary target for sexual function effects.

What the Research Shows

PT-141 has a relatively strong evidence base, including the Phase III trials that supported FDA approval, as well as earlier studies in male erectile dysfunction.

FDA Approval Studies (RECONNECT Trials)

The RECONNECT Phase III trials were the pivotal studies for FDA approval:

RECONNECT (n=1,247). Premenopausal women with HSDD were randomized to bremelanotide 1.75 mg subcutaneous injection vs. placebo, self-administered as needed before anticipated sexual activity.

Results:

• Statistically significant increase in satisfying sexual events (approximately 0.5 additional events per month vs. placebo)
• Significant improvement in sexual desire scores (FSDS-DAO scale)
• Significant reduction in distress related to low sexual desire
• The FDA advisory committee voted 14-2 in favor of approval

(Kingsberg et al., 2019)

The clinical effect was modest but real. The magnitude of improvement should be understood in context. HSDD is a complex condition. Even established treatments for sexual dysfunction tend to show modest effect sizes in clinical trials.

Erectile Dysfunction Studies (Men)

In Phase II studies for male erectile dysfunction, PT-141 demonstrated:

• Significant improvement in erection quality and duration
• Efficacy in some men who had not responded to PDE5 inhibitors. This is clinically significant because PDE5 non-responders represent an unmet medical need
• The intranasal route was initially explored but caused blood pressure elevations, shifting development to subcutaneous delivery

A study in men with ED and diabetes — a population often resistant to PDE5 inhibitors — showed PT-141 improved erectile function (Diamond et al., 2006).

PT-141 was not ultimately FDA-approved for male ED. The development pathway focused on women’s HSDD, partly because the male ED market was already served by PDE5 inhibitors.

Brain Imaging Studies

fMRI studies in women receiving PT-141 showed increased activation in brain regions associated with reward, motivation, and emotional processing when viewing erotic stimuli. This confirmed the central mechanism of action and supported classification as a “desire enhancer” rather than a “performance enhancer.”

How PT-141 Relates to Other Peptides

PT-141 occupies a unique niche in the peptide landscape as a centrally-acting sexual function compound.

• Kisspeptin-10 influences sexual function through the hormonal axis (increasing LH, testosterone, and estrogen production). PT-141 bypasses hormones entirely, acting directly on brain desire pathways. They address different aspects of sexual function: kisspeptin-10 targets hormone levels, PT-141 targets neurological desire.

• Melanotan II is PT-141’s parent compound. It activates the same melanocortin receptors but with broader activity, producing more pronounced tanning effects, appetite suppression, and sexual arousal. PT-141 was developed to be more selective for the sexual function effects. Melanotan II carries greater risk of side effects, including nevi (mole) changes.

• Selank addresses anxiety, which is sometimes a contributor to low sexual desire. For anxiety-driven sexual dysfunction, addressing the underlying anxiety may be relevant alongside or instead of direct desire enhancement.

• Ipamorelin and GH secretagogues are sometimes discussed in the context of overall vitality and libido, but they do not directly target sexual desire pathways. Any sexual function effects from GH optimization are indirect.

FDA-Approved Dosing (Vyleesi)

PT-141 is available as the FDA-approved product Vyleesi with established dosing parameters.

Vyleesi (Approved for HSDD in Premenopausal Women)

• Dose: 1.75 mg subcutaneous injection
• Timing: At least 45 minutes before anticipated sexual activity
• Maximum frequency: One dose per 24 hours; no more than 8 doses per month
• Delivery: Pre-filled auto-injector
• Indication: HSDD in premenopausal women

Community-Reported Off-Label Protocols

Community-reported protocols for off-label use should be understood in the context that only the Vyleesi indication has undergone full regulatory review.

Men (off-label):

• Reported dose: 1–2 mg subcutaneous injection
• Reported timing: 2–4 hours before anticipated activity (onset is slower than PDE5 inhibitors)
• Reported frequency: As needed, typically no more than 2–3 times per week

Lower-dose exploration:

• Some community members report effects at 500 mcg–1 mg
• Lower doses may reduce side effects (particularly nausea) while preserving some efficacy

Onset and Duration

• Onset: 45 minutes to 2 hours (notably slower than PDE5 inhibitors)
• Peak effect: 2–4 hours
• Duration: Effects may persist for 6–12 hours
• Important: PT-141 does not cause spontaneous, unprompted arousal. It enhances desire in the context of sexual stimuli.

Side Effects and Safety Considerations

PT-141’s side effect profile is well characterized from clinical trials involving over 1,200 patients.

Common Side Effects

• Nausea. The most common and dose-limiting side effect. Reported in approximately 40% of clinical trial participants. Often dose-dependent and tends to diminish with repeated use.
• Flushing. Facial warmth and redness, reported in 20–25% of participants.
• Headache. Reported in 10–15%.
• Injection site reactions. Standard subcutaneous injection effects.
• Transient skin darkening. Mild, temporary increase in pigmentation, particularly around the face and gums (MC1R effect). Usually fades within weeks and is much less pronounced than with Melanotan II.

Clinically Important Concerns

• Blood pressure elevation. PT-141 causes transient increases in blood pressure (average approximately 2–3 mmHg systolic, but potentially more significant in some individuals). The FDA label recommends against use in patients with uncontrolled hypertension or cardiovascular disease.
• Nausea severity. In some patients, nausea is severe enough to limit use. Anti-emetics (ondansetron) may help.
• Hyperpigmentation. While typically mild and transient, MC1R-mediated skin darkening can be uneven.

Contraindications (FDA Label)

• Uncontrolled hypertension
• Cardiovascular disease
• Concurrent naltrexone use (blocks melanocortin signaling)
• Not studied in postmenopausal women (the FDA indication is specific to premenopausal women)

Regulatory and Legal Status

United States

FDA-approved as Vyleesi (bremelanotide) for HSDD in premenopausal women. Available by prescription. Compounded and research chemical versions exist, but the approved pharmaceutical product represents the regulated pathway.

International

Regulatory status varies by country. Not approved in all markets. Available as a research chemical in many jurisdictions.

WADA

PT-141/bremelanotide is not currently explicitly listed on the WADA Prohibited List. The broader melanocortin agonist category may receive future scrutiny.

Frequently Asked Questions

Is PT-141 essentially “Viagra for women”?

No, and this comparison misrepresents both drugs. Sildenafil (Viagra) works on blood vessel mechanics and has no effect on desire. PT-141 works on brain desire pathways. They have fundamentally different mechanisms and address different aspects of sexual function. PT-141 is more accurately described as a desire enhancer than a performance enhancer.

Does PT-141 work for men?

Clinical studies demonstrate efficacy for male erectile dysfunction, including in some PDE5 inhibitor non-responders. It is not FDA-approved for this indication (development focused on women’s HSDD), but off-label use in men is discussed in clinical and community settings.

How can the nausea be managed?

Strategies reported in clinical practice and community experience include: starting at lower doses (1 mg or less), taking ondansetron (Zofran) 30 minutes before PT-141, eating a light meal 2 hours before injection, and noting that nausea often diminishes with repeated use.

Will PT-141 cause a tan?

Mild, temporary skin darkening is possible through MC1R activation. The effect is substantially less pronounced than with Melanotan II. Most individuals at standard doses notice minimal to no visible skin color change.

Can PT-141 be combined with PDE5 inhibitors (Viagra/Cialis)?

This combination has been discussed in clinical settings but is not well studied. The theoretical concern is additive blood pressure effects. Anyone considering this combination should consult a healthcare provider. The two drugs address different aspects of sexual function (desire vs. mechanics) and could theoretically be complementary, but safety data for the combination is limited.

Is PT-141 appropriate for sexual dysfunction caused by antidepressants?

SSRI-induced sexual dysfunction is common and often involves reduced desire — which is the domain PT-141 targets. However, the RECONNECT trials excluded patients with medication-induced sexual dysfunction, so direct evidence for this specific population is limited. Some clinicians have explored this application. Discussion with a prescribing healthcare provider is appropriate.

References

1. Kingsberg SA, et al. “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.” Obstet Gynecol. 2019;134(5):899-908. PubMed
2. Diamond LE, et al. “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141).” J Sex Med. 2006;3(4):628-38. PubMed
3. Pfaus JG, et al. “A review of animal and human data on the melanocortin system and sexual function.” Eur J Pharmacol. 2013;704(1-3):270-9. PubMed
4. Clayton AH, et al. “Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.” Womens Health. 2016;12(3):325-37.
5. Molinoff PB, et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Ann N Y Acad Sci. 2003;994:96-102. PubMed
6. Safarinejad MR. “Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder.” J Sex Med. 2008;5(4):827-34. PubMed

Related Articles

Peptide

Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

An evidence-first review of ipamorelin, covering its selectivity compared to other GHRPs, what clinical and preclinical research has demonstrated, and what remains unknown.

Peptide

Kisspeptin-10: Research, Mechanism, and Evidence for Reproductive Hormone Regulation

An evidence-based review of Kisspeptin-10 — the neuropeptide that regulates the HPG axis. Clinical research on LH, testosterone, fertility applications, and practical limitations.

Peptide

Selank: Research, Mechanism, and Clinical Evidence for Anxiety and Cognition

An evidence-based review of Selank — the tuftsin-derived heptapeptide studied for anxiolytic and nootropic effects. Russian clinical data, mechanism of action, and what is known.